Slotved H-C, Jacobsen J N, Møller H K, Krogfelt K A
Department of Bacteriology, Mycology and Parasitology, Division of Microbiology and Diagnostics, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark.
Vaccine. 2007 Mar 22;25(13):2513-7. doi: 10.1016/j.vaccine.2006.09.028. Epub 2006 Sep 20.
Streptococcus pneumoniae (pneumococcus) is a significant cause of morbidity and mortality in infants and elderly people. Pneumococcal strains possess a polysaccharide capsule, and 90 different serotypes have been identified. The pneumococcal ELISA suggested by World Health Organization (WHO) guidelines is based on capsular serotypes included in the 23-valent polysaccharide vaccine (Pneumovax((R))). Pneumococcal antigens were developed and applied in an ELISA, which elicited a low baseline cross-reaction with the common cell wall polysaccharide (C-Ps). The aim of this study was to develop an ELISA using type-specific antigens from S. pneumoniae strains with serotypes of own selection in order to quantify type-specific pneumococcal antibodies in human serum.
肺炎链球菌是婴幼儿和老年人发病及死亡的重要原因。肺炎链球菌菌株具有多糖荚膜，已鉴定出90种不同的血清型。世界卫生组织（WHO）指南推荐的肺炎球菌酶联免疫吸附测定（ELISA）基于23价多糖疫苗（沛儿（Pneumovax((R))））中包含的荚膜血清型。开发了肺炎球菌抗原并将其应用于ELISA中，该抗原与常见细胞壁多糖（C-Ps）引发低基线交叉反应。本研究的目的是使用来自自行选择血清型的肺炎链球菌菌株的型特异性抗原开发一种ELISA，以定量人血清中的型特异性肺炎球菌抗体。
